行情

BIOC

BIOC

Biocept
NASDAQ

实时行情|Nasdaq Last Sale

0.7710
+0.0072
+0.94%
盘前: 0.7690 -0.002 -0.26% 09:00 10/21 EDT
开盘
0.7900
昨收
0.7638
最高
0.7900
最低
0.7400
成交量
3,000
成交额
--
52周最高
3.720
52周最低
0.6580
市值
1,774.71万
市盈率(TTM)
-0.1595
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BIOC 新闻

  • Why Biocept, Inc.'s (NASDAQ:BIOC) CEO Pay Matters To You
  • Simply Wall St..6天前
  • Biocept's Target Selector ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
  • PR Newswire.10/07 13:05
  • Biocept nabs new patent in South Korea
  • seekingalpha.10/03 17:33
  • Biocept Announces Issuance of South Korean Patent Covering its Target Selector Oncogene Mutation Enrichment and Detection Platform
  • PR Newswire.10/03 13:05

更多

所属板块

医疗设备、用品及经销
+0.02%
医疗设备和用品
+0.23%

热门股票

名称
价格
涨跌幅

BIOC 简况

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
展开

Webull提供Biocept Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。